RGEN

Repligen Corp. 10-Q Summary: Quarter Ended June 30, 2006

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2006 for Repligen Corporation, a biopharmaceutical company focused on developing therapeutics for central nervous system diseases. The company generates revenue primarily from the sale of Protein A products for monoclonal antibody purification and SecreFlo for pancreatic disorder assessment. The company operates as a single segment.

Key Financial Metrics

Margins: Gross margin for the quarter was approximately 72.7% (Revenue $3.63M vs. Cost of Product Revenue $0.99M). The filing does not explicitly state a net profit margin percentage, but net income was $100,734 on revenue of $3,628,168.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by 14% ($611,000) compared to the prior year quarter. This was primarily driven by a decrease in Protein A sales volume ($2.94M vs. $3.48M).
• Operating Expenses Increase: Total operating expenses rose 12% ($391,000). Selling, general, and administrative (SG&A) expenses increased 29% ($346,000), largely due to a $190,000 increase in stock-based compensation expense following the adoption of SFAS No. 123R.
• Net Income Volatility: Net income dropped significantly from $2.19M in Q2 2005 to $101k in Q2 2006. The prior year included a one-time $1.17M "Other Income" gain from the reversal of accrued royalties related to a settlement with ChiRhoClin, Inc., which did not recur in the current period.
• Cash Flow Shift: Operating cash flow turned negative ($305k used) compared to positive ($1.21M provided) in the prior year, driven by an increase in accounts receivable ($515k) and prepaid expenses.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash and investment balances ($22.5M) are adequate to meet needs for at least the next 24 months. The company expects to incur approximately $500,000 in capital expenditures over the next six months to expand its Protein A manufacturing facility.
• Accounting Changes: The company adopted SFAS No. 123R (Share-Based Payment) effective April 1, 2006, resulting in the recognition of approximately $249,000 in stock-based compensation expense for the quarter, reducing EPS by $0.01.
• Legal Proceedings (ImClone): In July 2006 (subsequent to period end), a U.S. District Court issued a Summary Judgment in favor of Repligen and MIT against ImClone Systems regarding patent infringement for the drug Erbitux. The court rejected ImClone's defense of patent exhaustion. Repligen intends to seek damages for unlicensed use of patented technology.
• Risks: Key risks include dependence on collaborative arrangements, the success of clinical trials for CNS therapeutics, regulatory approvals, and the depletion of SecreFlo supplies from ChiRhoClin, after which the company will cease marketing that specific product.

Investor Verification Checklist

• Revenue Concentration: Verify the impact of customer concentration; two customers accounted for approximately 75% of product revenue in Q2 2006, and one customer held 59% of accounts receivable.
• Patent Litigation Status: Monitor the ongoing ImClone litigation for potential damage awards or settlement terms following the favorable summary judgment.
• SecreFlo Supply Chain: Confirm the timeline for the depletion of SecreFlo inventory supplied by ChiRhoClin and the transition plan for that revenue stream.
• Stock-Based Compensation: Review the impact of SFAS 123R adoption on future quarterly expenses and earnings per share.
• Capital Expenditures: Track the $500,000 planned investment in manufacturing expansion and its effect on cash reserves.